Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...

U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Dr. Bruce Montgomery, a UW Medicine oncologist, hopes that ...

U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Prostate cancer statistics can look scary: 34,250 U.S. deaths in 2024. 1.4 million new cases worldwide in 2022. Dr. Bruce Montgomery, a UW ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels.

New research from Edith Cowan University (ECU) has confirmed that erectile dysfunction in patients living with prostate ...

Prostate cancer remains one of the most commonly diagnosed cancersworldwide, with 1.4 million new cases and over 375,000 ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer. Dr. Debu Tripathy breaks down the FDA approval ...

12, 2025 — Metastatic ... skin cancer by 68%. This study is among the few to examine the relationship between perceived cancer risk, concern about ... Mar. 10, 2025 — Prostate cancer ...

Archie Emanuel, Jr., a Vietnam-era veteran, remembered the day he received his diagnosis. “I had all the blood work and the urologist found out I had cancer,” he said. “It hit me so hard. Cancer! Here ...

In this video, Dr Louise Kostos discusses patient subgroups that see the most benefit from triplet regimens incorporating docetaxel in metastatic hormone-sensitive prostate cancer. She is an author of ...